Betaxolol Uses, Dosage, Side Effects & Warnings | DrugsAtlas
Authoritative Clinical Reference
Navigation
DRUG NAME: Betaxolol
Therapeutic Class: Beta-Adrenergic Blocker
Subclass: Selective β1-Adrenergic Receptor Antagonist
Speciality: Cardiology
Schedule (India): H
Route(s): Oral, Ophthalmic
Formulations Available in India:
- Oral tablet: 10 mg, 20 mg
- Ophthalmic solution (eye drops): 0.25%, 0.5%
INDICATIONS + DOSING — FOR CLINICIAN USE ONLY
Primary Indications (Approved / Standard in India)
1. Systemic Hypertension (Oral)
| Parameter | Recommendation |
| Starting dose | 10 mg once daily |
| Titration | May increase to 20 mg once daily after 1–2 weeks if BP control inadequate |
| Usual maintenance dose | 10–20 mg once daily |
| Maximum dose | 40 mg/day |
Clinical notes:
- Highly β1-selective; may be considered in patients with mild reactive airway disease where beta-blockade is clinically indicated (use with caution)
- Administer at the same time each day for consistent effect
- Do not discontinue abruptly; taper over 1–2 weeks
2. Open-Angle Glaucoma / Ocular Hypertension (Ophthalmic)
| Parameter | Recommendation |
| Starting dose | 1 drop of 0.25% or 0.5% solution into affected eye(s) twice daily |
| Titration | Not applicable |
| Usual maintenance dose | 1 drop twice daily |
| Maximum dose | 2 applications per day per eye |
Clinical notes:
- Preferred ophthalmic beta-blocker in patients with asthma or bronchospastic disease due to β1-selectivity
- Advise punctal occlusion (nasolacrimal compression) for 1–2 minutes after instillation to minimize systemic absorption
- May take 2–4 weeks to achieve full IOP-lowering effect
Secondary Indications – Adults (Off-label, if any)
Not applicable. No off-label indications with established evidence or widespread use in Indian clinical practice.
PAEDIATRIC DOSING (Specialist Only)
Primary Indications (Approved / Standard in India)
Paediatric Glaucoma (Ophthalmic) – Specialist supervision mandatory
| Age Group | Dose | Clinical Notes |
| ≥2 years | 1 drop of 0.25% solution into affected eye(s) twice daily | Use under paediatric ophthalmologist supervision |
Safety monitoring:
- Monitor for systemic beta-blockade effects: bradycardia, hypotension, bronchospasm, lethargy
- Assess baseline heart rate and respiratory status before initiating therapy
- Punctal occlusion essential to reduce systemic absorption in children
Age restriction: Not recommended below 2 years of age without specialist input and close monitoring.
Oral formulation: Not routinely used in paediatric population in India; no established dosing guidelines.
Secondary Indications – Paediatrics (Off-label, if any)
Not applicable. No established off-label paediatric indications in Indian practice.
RENAL ADJUSTMENT
| Renal Function | Recommendation |
| Mild to moderate impairment (CrCl ≥30 mL/min) | No dose adjustment required |
| Severe impairment (CrCl <30 mL/min) | Use with caution; monitor for bradycardia and hypotension with oral formulation |
| Haemodialysis | Betaxolol is not significantly dialysable; no supplemental dose required |
HEPATIC ADJUSTMENT
| Hepatic Function | Recommendation |
| Mild impairment (Child-Pugh A) | No dose adjustment required |
| Moderate impairment (Child-Pugh B) | Start at lower dose (5–10 mg/day orally); titrate cautiously |
| Severe impairment (Child-Pugh C) | Avoid oral formulation or use with extreme caution; risk of drug accumulation |
Note: Ophthalmic formulation has minimal systemic exposure; generally safe in hepatic impairment.
CONTRAINDICATIONS
- Sinus bradycardia (<50 bpm)
- Second- or third-degree atrioventricular block (without functioning pacemaker)
- Sick sinus syndrome
- Cardiogenic shock
- Decompensated heart failure
- Severe bronchial asthma or severe COPD (for oral formulation)
- Hypersensitivity to betaxolol or any excipient in the formulation
- Concurrent intravenous verapamil or diltiazem administration
CAUTIONS
- Mild to moderate asthma or COPD: Ophthalmic route preferred; oral use only if essential and with close respiratory monitoring
- Diabetes mellitus: May mask warning symptoms of hypoglycaemia (tachycardia, tremor); counsel patient accordingly
- Peripheral vascular disease / Raynaud’s phenomenon: May worsen symptoms
- First-degree AV block: Use with caution; monitor for progression
- Myasthenia gravis: May exacerbate muscle weakness
- History of anaphylaxis: Beta-blockers may reduce response to adrenaline
- Thyrotoxicosis: May mask clinical signs; avoid abrupt withdrawal
- Elderly: Increased sensitivity to hypotensive and bradycardic effects
- Depression: Use with caution; may exacerbate symptoms
- Pheochromocytoma: Do not use without prior alpha-blockade
Important: Do not stop oral betaxolol abruptly after long-term use; taper gradually over 1–2 weeks to prevent rebound hypertension or angina.
PREGNANCY
| Parameter | Recommendation |
| Overall safety | Not preferred for systemic use; beta-blockers may cause fetal bradycardia, hypoglycaemia, and intrauterine growth restriction |
| Ophthalmic use | May be used if benefit justifies risk; systemic absorption is low but possible |
| Preferred alternatives (systemic hypertension) | Labetalol, methyldopa |
| Monitoring | Fetal heart rate monitoring, serial growth scans if used beyond first trimester |
LACTATION
| Parameter | Recommendation |
| Oral formulation | Use with caution; betaxolol is excreted in breast milk in small amounts |
| Ophthalmic formulation | Generally considered compatible; minimal systemic absorption |
| Expected milk levels | Low (based on limited data) |
| Preferred alternative (systemic use) | Metoprolol, propranolol |
| Infant monitoring | Heart rate, feeding behaviour, alertness, weight gain |
ELDERLY
| Parameter | Recommendation |
| Starting dose (oral) | 5–10 mg once daily |
| Titration | Slow titration; increase dose only after 2–3 weeks if tolerated |
| Specific risks | Increased risk of orthostatic hypotension, bradycardia, falls, and cognitive effects |
| Monitoring | Regular BP (including orthostatic), heart rate, renal function assessment |
MAJOR DRUG INTERACTIONS
| Interacting Drug | Effect / Risk | Management |
| Verapamil / Diltiazem (especially IV) | Severe bradycardia, AV block, asystole | Avoid concurrent IV use; oral combination requires close monitoring |
| Clonidine | Rebound hypertension if clonidine stopped abruptly | Withdraw betaxolol first, then taper clonidine |
| Class I antiarrhythmics (disopyramide, quinidine, flecainide) | Additive negative inotropic and dromotropic effects | Avoid combination or use with extreme caution |
| MAO inhibitors | Severe hypertensive reaction possible | Avoid concurrent use |
| Anaesthetic agents (e.g., enflurane, halothane) | Additive myocardial depression | Inform anaesthetist; may need to withdraw beta-blocker pre-operatively |
MODERATE DRUG INTERACTIONS
| Interacting Drug | Effect / Risk | Management |
| NSAIDs (ibuprofen, diclofenac) | May attenuate antihypertensive effect | Monitor BP; consider alternative analgesic |
| Rifampicin | Hepatic enzyme induction; reduced betaxolol levels | Monitor BP; dose adjustment may be needed |
| Digoxin | Additive bradycardia risk | Monitor pulse regularly |
| Amiodarone | Additive risk of bradycardia and AV block | Avoid if possible; if used, monitor closely |
| Insulin / Sulfonylureas | Masking of hypoglycaemia symptoms | Counsel diabetic patients; monitor blood glucose |
| Ergot alkaloids | Increased peripheral vasoconstriction | Avoid combination |
| Antipsychotics (phenothiazines) | Additive hypotension | Monitor BP |
COMMON ADVERSE EFFECTS
Oral formulation:
- Fatigue, asthenia
- Dizziness, headache
- Bradycardia
- Cold extremities
- Gastrointestinal disturbances (nausea, diarrhoea)
- Sleep disturbances
Ophthalmic formulation:
- Transient stinging or burning on instillation
- Blurred vision (transient)
- Ocular discomfort, dryness
- Tearing
SERIOUS ADVERSE EFFECTS
| Adverse Effect | Action Required |
| Severe bradycardia (<45 bpm) or symptomatic heart block | Discontinue immediately; consider atropine or temporary pacing |
| Bronchospasm (especially in susceptible patients) | Discontinue; administer bronchodilator therapy |
| Acute decompensated heart failure | Discontinue; initiate appropriate heart failure management |
| Severe hypotension | Withhold drug; IV fluids, vasopressors if needed |
| Stevens-Johnson syndrome / Toxic epidermal necrolysis (rare) | Discontinue permanently; urgent dermatology/intensive care referral |
| Worsening depression or suicidal ideation | Discontinue; psychiatric evaluation |
MONITORING REQUIREMENTS
| Phase | Parameters |
|
Baseline (Oral)
|
Blood pressure, heart rate, ECG (if cardiac disease suspected), renal and hepatic function tests, blood glucose (in diabetics) |
|
Baseline (Ophthalmic)
|
Intraocular pressure (IOP), visual acuity, slit-lamp examination, fundoscopy |
|
After initiation (Oral)
|
BP and HR within 1–2 weeks; repeat at each dose titration |
|
After initiation (Ophthalmic)
|
IOP check at 2–4 weeks |
|
Long-term (Oral)
|
BP and HR monthly until stable, then 3-monthly; periodic ECG in cardiac patients; annual renal/hepatic function |
|
Long-term (Ophthalmic)
|
IOP every 3–6 months; annual visual field and optic disc assessment |
BRANDS AVAILABLE IN INDIA
Oral formulations:
- Betacard®
- Betanorm®
Ophthalmic formulations:
- Betoptic® Eye Drops
- Betoptic-S® (suspension)
- Optobet®
PRICE RANGE (INR)
| Formulation | Approximate Price |
| Oral tablets (10 mg, 10 tablets) | ₹60–₹100 |
| Oral tablets (20 mg, 10 tablets) | ₹80–₹120 |
| Eye drops 0.5% (5 mL) | ₹80–₹130 |
| Eye drops 0.25% (5 mL) | ₹60–₹100 |
Note: Not currently under NPPA price control. Prices may vary by region and pharmacy.
CLINICAL PEARLS
- Respiratory safety: Betaxolol is the most β1-selective among ophthalmic beta-blockers; preferred in glaucoma patients with mild asthma or COPD, though not absolutely contraindicated like non-selective agents.
- Punctal occlusion: Always counsel patients to apply nasolacrimal compression for 1–2 minutes after instilling eye drops to minimize systemic absorption and reduce risk of bradycardia or bronchospasm.
- Gradual withdrawal: Never stop oral betaxolol abruptly after prolonged use; taper over 1–2 weeks to prevent rebound hypertension, angina, or even myocardial infarction.
- Diabetic patients: Warn patients that typical hypoglycaemia warning symptoms (tachycardia, tremor) may be masked; sweating remains a reliable indicator.
- Efficacy onset: Ophthalmic betaxolol may take 2–4 weeks to demonstrate full IOP reduction; reassess response before concluding treatment failure.
- Alternative to timolol: In patients who develop respiratory side effects with timolol eye drops, betaxolol is a reasonable cardioselective alternative.
TAGS
Betaxolol; hypertension; beta-blocker; cardioselective; β1-selective; glaucoma; ocular-hypertension; ophthalmic; asthma-compatible; antihypertensive
VERSION
RxIndia v1.0 — 14 Feb 2026
REFERENCES
- CDSCO Product Database and Approved Drug Labels
- Indian Pharmacopoeia (IP)
- API Textbook of Medicine
- AIIMS Hospital Formulary and Department Protocols
- Indian Journal of Ophthalmology (Glaucoma Management Guidelines)
- ICMR Guidelines for Management of Hypertension in India
- WHO Model List of Essential Medicines (supportive reference for ophthalmic use)
- Goodman & Gilman’s The Pharmacological Basis of Therapeutics (pharmacology reference)
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.